. 2021 Sep 16;21:131. doi: 10.1186/s12894-021-00897-2

Table 6.

Logistic regression analyses predicting the probability of Gleason score ≥ 7 disease

Predictors	AUC of individual predictor variable (95% CI);) P value*	Bivariate analysis OR(95%CI); P value	Multivariate analysis
Age	0.55 (0.42–0.67) 0.508	1.028 (0.95–1.12); 0.513	1.005 (0.92–1.09); 0.913	1.050 (0.95–1.16); 0.357	1.028 (0.93–1.13); 0.577
tPSA, ng/mL	0.62 (0.48–0.77) –	1.064 (0.99–1.14); 0.086	1.031 (0.92–1.16); 0.602	1.016 (0.940–1.098); 0.688	0.974 (0.90–1.05); 0.498
fPSA	0.58 (0.44–0.72) 0.358	1.818 (0.84–3.94); 0.129	1.399 (0.39–5.04); 0.608	0.943 (0.36–2.46); 0.904	0.727 (0.28–1.88); 0.511
%fPSA	0.41 (0.26–0.57) 0.302	0.973 (0.91–1.04); 0.440	0.977 (0.88–1.09); 0.675	0.978 (0.86–1.11); 0.731	1.010 (0.90–1.13); 0.869
p2PSA, pg/mL	0.79 *(0.68–0.91)0.004***	1.047 (1.01–1.09); 0.017	–	–	–
%p2PSA	0.86 *(0.75–0.93)0.001***	1.020 (1.01–1.04); 0.007	–	1.029 *(1.01–1.05);0.015***	–
PHI	0.87 (0.76–0.94) *< 0.001*	3.887 (1.73–8.74); 0.001	–	–	3.833 *(1.56–9.40);0.003***
AUC of multivariate models (95% CI)	–	–	0.629 (0.50–0.75) 0.086	0.861 (0.75–0.94) *< 0.001*	0.886 (0.78–0.95) *< 0.001*
Gain in predictive accuracy (95% CI); P value	–	–	–	0.232 (0.08–0.38); *0.002*	0.257 (0.11–0.40); *0.001*

Predictors

AUC of individual predictor variable (95% CI);)
P value*

Bivariate analysis
OR(95%CI); P value

Multivariate analysis

Base model **
OR(95% CI); P value

Base model + %p2PSA
OR (95% CI); P value

Base model + PHI
OR(95%CI); P value

Age

0.55

(0.42–0.67) 0.508

1.028

(0.95–1.12); 0.513

1.005

(0.92–1.09); 0.913

1.050

(0.95–1.16); 0.357

1.028

(0.93–1.13); 0.577

tPSA, ng/mL

0.62

(0.48–0.77) –

1.064

(0.99–1.14);

0.086

1.031

(0.92–1.16); 0.602

1.016

(0.940–1.098); 0.688

0.974

(0.90–1.05); 0.498

fPSA

0.58

(0.44–0.72) 0.358

1.818

(0.84–3.94); 0.129

1.399

(0.39–5.04); 0.608

0.943

(0.36–2.46); 0.904

0.727

(0.28–1.88); 0.511

%fPSA

0.41

(0.26–0.57) 0.302

0.973

(0.91–1.04); 0.440

0.977

(0.88–1.09); 0.675

0.978

(0.86–1.11); 0.731

1.010

(0.90–1.13); 0.869

p2PSA, pg/mL

0.79

(0.68–0.91)0.004

1.047

(1.01–1.09); 0.017

–

%p2PSA

0.86

(0.75–0.93)0.001

1.020

(1.01–1.04); 0.007

–

1.029

(1.01–1.05);0.015

–

PHI

0.87

(0.76–0.94) < 0.001

3.887

(1.73–8.74); 0.001

–

3.833

(1.56–9.40);0.003

AUC of multivariate models (95% CI)

–

0.629

(0.50–0.75)

0.086

0.861

(0.75–0.94)

< 0.001

0.886

(0.78–0.95)

< 0.001

Gain in predictive accuracy (95% CI);

P value

–

0.232

(0.08–0.38);

0.002

0.257

(0.11–0.40);

0.001

AUC, area under the receiver operating characteristic curve; PSA, prostate-specific antigen; fPSA, free PSA; p2PSA, [-2]proPSA; PHI, prostate health index; tPSA, total PSA; OR, odds ratio; CI, confidence interval

*P value: Comparison of AUC using tPSA as standard

**Base model includes age, tPSA, fPSA and %fPSA

P value to be statiscally significant with bolditalics